IP Library Granted Patent US 6,838,256
Granted Patent B2
US 6,838,256 · App. 09/734,672 · Granted Jan 4, 2005

Coding sequences of the human BRCA1 gene

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,838,256
App. No.
09/734,672
Granted
Jan 4, 2005
Kind
B2
Abstract

isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1 (omi1) , BRCA1 (omi2) , and BRCA1 (omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences.

Claims (16)

1. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 3.

2. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid consists essentially of the nucleotide sequence of SEQ ID NO: 3.

3. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid molecule consists of the nucleotide sequence of SEQ ID NO: 3.

4. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises nucleotides 120 to 5,708 of SEQ ID NO: 3.

5. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid molecule consists of nucleotides 120 to 5,708 of SEQ ID NO: 3.

6. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is operably linked to one or more expression control elements.

7. A vector comprising an isolated nucleic acid molecule of claim 1 .

8. A host cell comprising the vector of claim 7 .

9. A host cell transformed to contain the nucleic acid molecule of claim 1 .

10. A host cell of claim 8 or 9 , wherein said host is selected from the group consisting of prokaryotic hosts and eukaryotic hosts.

11. A method for producing a polypeptide comprising culturing a host cell of claim 8 or 9 under in vitro conditions in which the protein encoded by the nucleic acid molecule is expressed.

12. A method for producing a polypeptide comprising culturing a host cell containing a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 3 under in vitro conditions in which the protein encoded by the nucleic acid molecule is expressed.

13. The method of claim 12 , wherein the nucleic acid consists essentially of the nucleotide sequence of SEQ ID NO: 3.

14. The method of claim 12 , wherein the nucleic acid molecule consists of the nucleotide sequence of SEQ ID NO: 3.

15. The method of claim 12 , wherein the nucleic acid molecule comprises nucleotides 120 to 5,708 of SEQ ID NO: 3.

16. The method of claim 12 , wherein the nucleic acid molecule consists of nucleotides 120 to 5,708 of SEQ ID NO: 3.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2010
From: ORE PHARMACEUTICALS, INC.
To: MYRIAD GENETICS, INC.
Reel/Frame 024055/0559 →
MERGER Recorded May 24, 2002
From: GENE LOGIC ACQUISITION CORPORATION
To: GENE LOGIC INC.
Reel/Frame 012931/0499 →